摘要
目的分析安罗替尼治疗老年肺癌伴脑转移患者的近远期效果及安全性。方法选取48例老年肺癌伴脑转移患者,通过抽签法分为对照组和试验组,各24例。对照组患者进行放射治疗,试验组患者在对照组基础上给予安罗替尼口服治疗。对比两组患者近期治疗效果、治疗期间不良反应发生情况及远期生存率。结果治疗12周后,试验组患者客观有效率、疾病控制率分别为70.83%、91.67%,高于对照组的41.67%、66.67%(P<0.05)。试验组患者1、2年生存率分别为87.50%、66.67%,均显著高于对照组的58.33%、37.50%(P<0.05)。两组患者恶心呕吐、骨髓抑制、腹泻、疲乏、肝功能异常发生率比较,不具有统计学差异(P>0.05)。结论安罗替尼治疗老年肺癌伴脑转移患者,能够显著提高近期治疗效果,有效延长患者的生存时间,且毒副作用可耐受,患者治疗期间相关不良反应无明显增加。
Objective To analyze the short-term and long-term efficacy and safety of anlotinib in the treatment of elderly patients with lung cancer and brain metastases.Methods A total of 48 elderly patients with lung cancer and brain metastases were divided into control group and experimental group according to lottery method,with 24 cases in each group.Patients in the control group received radiation therapy,and patients in the experimental group were given oral anlotinib based on the control group.The short-term therapeutic effect,occurrence of adverse reactions during treatment and the long-term survival rate were compared between the two groups.Results After 12 weeks of treatment,the objective effective rate and disease control rate of the experimental group were 70.83%and 91.67%,which were higher than 41.67%and 66.67%of the control group(P<0.05).The 1-year and 2-year survival rates of the experimental group were 87.50%and 66.67%,which were significantly higher than 58.33%and 37.50%of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion For elderly patients with lung cancer and brain metastasis,anlotinib can significantly improve the short-terms outcomes of patients,effectively prolong the survival time of patients,and the toxic side effects can be tolerated,and there is no significant increase in the adverse reactions during the treatment.
作者
王朝霞
吕明健
WANG Zhao-xia;LYU Ming-jian(Gaomi People's Hospital,Weifang 261500,China)
出处
《中国现代药物应用》
2025年第10期85-87,共3页
Chinese Journal of Modern Drug Application
关键词
安罗替尼
老年
肺癌
脑转移
效果
安全性
Anlotinib
Old age
Lung cancer
Brain metastases
Effect
Safety
